NSAIDs and developmental toxicity.
Tassinari
Melissa S
MS
Pfizer Global Research & Development, Drug Safety Evaluation, Groton, Connecticut 06340, USA. melissa_s_tassinari@groton.pfizer.com
Cook
Jon C
JC
Hurtt
Mark E
ME
D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D000328:Adult; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000633:toxicity*; D051545:Cyclooxygenase 1; D016861:Cyclooxygenase Inhibitors / Q000633:toxicity; D005260:Female; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D008565:Membrane Proteins; D011247:Pregnancy; D011451:Prostaglandin-Endoperoxide Synthases; D011817:Rabbits; D051381:Rats; D013723:Teratogens / Q000633:toxicity*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D013723:Teratogens; D051545:Cyclooxygenase 1; C496511:PTGS1 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; C496513:Ptgs1 protein, rat